Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 8, 2009

BioFocus Gains Access to DiscoveRx GPCR and cAMP Assays

  • BioFocus and DiscoveRx signed a co-marketing agreement that will allow BioFocus to carry out screening for clients using DiscoveRx' PathHunter™ ß-Arresting GPCR screening assay, HitHunter™ cAMP assays, and associated cell lines.

    The deal with BioFocus comes just days after DiscoveRx signed a global agreement with GlaxoSmithKline to provide the latter with access to its PathHunter™ ß-Arrestin parental cell lines, clones, and associated reagents for use in GSK's GPCR screening and profiling research. This agreement followed closely behind DiscoveRx and GSK's announcement of a three-way alliance with Medical Research Council Technology, focused on using the PathHunter™ ß-Arrestin assay technology to find binders to orphan GPCRs.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »